The dose of Praluent® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg Q2W or 300 mg once Q4W (monthly), the dosage may be adjusted to the maximum dosage of 150 mg Q2W.
If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.
CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.